Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Effects of Phenytoin on Belzutifan PK in Healthy Adults
NCT06903715Phase 1Completed
- Sponsor
- Merck & Co.
- Start
- Mar 2025
- Primary completion
- May 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of belzutifan in renal cell carcinoma (RCC) and von Hippel–Lindau disease (VHL), sponsored by Merck & Co. Primary endpoint: Area Under the Concentration-Time Curve from Time 0 to Infinity. Started Mar 2025; status: completed.
02
Drugs
belzutifan
03
Conditions
renal cell carcinoma (RCC)von Hippel–Lindau disease (VHL)
Beyond the preview
Go deeper on NCT06903715.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06903715.